Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1995)	5/18/1998 4:54:00 AM
From: Henry Niman	Respond to of 4676

I was responding to the post indicating that the Barron's Biotech article included discussions of Biotechs in general as well as Cancer Biotechs in particular. Speaking of Cancer Biotech, today's WSJ has an article on GNE's Herceptin (and it's linked to the front page at wsj.com ). That article also mentions LGND and SRGN (there is some analogy and relatedness between Herceptin and DAB389-EGF, a LGND/SRGN fusion toxin in trials for various cancers including breast cancer.